Molecular Docking Analysis of Berberis aristata Phytocompounds as Potential Growth Factor Receptor Blockers in Cancer Therapy

Year : 2025 | Volume : 03 | Issue : 02 | Page : 1 10
    By

    Sivakumarreddy Bapatu,

  1. Student, Department of Biomedical Engineering, University of Bridgeport, Bridgeport, CT, , United States

Abstract

Middle-aged and older women are susceptible to breast cancer (BC), a potentially fatal condition. When breast cancer is diagnosed, the median age is 62. Breast cancer diagnoses in women under 45 are comparatively uncommon, whereas the bulk of breast cancer diagnoses occur in women 62 and older. Growth factor receptors are interesting therapeutic targets because of their critical role in the pathophysiology of cancer. Vascular endothelial growth factor receptors (VEGFR-2) and human epidermal growth factor receptors (HER-2) have a role in the development and spread of cancer. To determine their HER-2 binding affinity, 39 phytocompounds from Berberis aristata were chosen. PyRx, a virtual screening tool, was used for molecular docking. Databases including PubChem, Indian medicinal plants, phytochemistry, and therapeutics were used to obtain the molecular structures of the compounds and the targeted proteins. Protein Data Bank sum generation and BIOVIA Discovery Studio tools were used to validate the protein structures. Additionally, ADMET was used to assess the ligands’ pharmacokinetic characteristics.

Keywords: Breast cancer (BA), Human epidermal growth factor receptors (HER-2), ADMET analysis, Molecular docking, Berberis aristata (BA)

[This article belongs to International Journal of Cell Biology and Cellular Functions ]

How to cite this article:
Sivakumarreddy Bapatu. Molecular Docking Analysis of Berberis aristata Phytocompounds as Potential Growth Factor Receptor Blockers in Cancer Therapy. International Journal of Cell Biology and Cellular Functions. 2025; 03(02):1-10.
How to cite this URL:
Sivakumarreddy Bapatu. Molecular Docking Analysis of Berberis aristata Phytocompounds as Potential Growth Factor Receptor Blockers in Cancer Therapy. International Journal of Cell Biology and Cellular Functions. 2025; 03(02):1-10. Available from: https://journals.stmjournals.com/ijcbcf/article=2025/view=229180


References

  1. Uniyal MR, Tewari LC. Anti-cancer drugs from U.P. Himalaya. Ancient Sci Life. 1991;11(1–2):50–5.
  2. Fenninger LD, Mider GB. Energy and nitrogen metabolism in cancer. Adv Cancer Res. 1954;2:229–53.
  3. Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbot BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep. 1972;3:1–86.
  4. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol. 2008;66:65–74.
  5. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
  6. Vostakolaei FA, Karim-Kos HE, Janssen-Heijnen MLG, Visser O, Verbeek ALM, Kiemeney L. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health. 2010;21:573–7.
  7. Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: A population-based study. Lancet Oncol. 2010;11:165–73.
  8. Rauf A, Abu-Izneid T, Khalil AA, Imran M, Shah ZA, Emran TB, et al. Berberine as a potential anticancer agent: A comprehensive review. Molecules. 2021;26:7368.
  9. Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. miRNAs as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis. Cells. 2020;9:276.
  10. Mann J. Natural products in cancer chemotherapy: Past, present and future. Nat Rev Cancer. 2002;2:143–8.
  11. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RPB, Aparna SR, Mangalapandi P, et al. IMPPAT: A curated database of Indian medicinal plants, phytochemistry and therapeutics. Sci Rep. 2018;8(1):4329.
  12. Hao DC, Hou XD, Gu XJ, Xiao PG, Ge GB. Ethnopharmacology, chemodiversity, and bioactivity of Cephalotaxus medicinal plants. Chin J Nat Med. 2021;19(5):321–38.
  13. Sahu N, Mishra S, Kesheri M, Kanchan S, Sinha RP. Identification of cyanobacteria-based natural inhibitors against SARS-CoV-2 druggable target ACE2 using molecular docking study, ADME and toxicity analysis. Indian J Clin Biochem. 2023;38(3):361–73.
  14. Sakhawat A, Khan MU, Rehman R, Khan S, Shan MA, Batool A, et al. Natural compound targeting BDNF V66M variant: Insights from in silico docking and molecular analysis. AMB Express. 2023;13(1):134.
  15. Shakil S. Molecular interaction of investigational ligands with human brain acetylcholinesterase. J Cell Biochem. 2019;120(7):11820–30.
  16. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49(W1):W5–14.
  17. Chakravarti KK, Dhar DC, Siddiqui S. Alkaloidal constituents of the bark of Berberis aristata. J Sci Ind Res. 1950;9B:161–4.
  18. Upwar NK, Patel R, Waseem N, Mahobia NK. Pharmacognostic evaluation of stem of Berberis aristata Pharmacogn J. 2010;2:5–9.
  19. Srivastava SK, Khatoon S, Rawat AK, Mehrotra S, Pushpangadan P. Pharmacognostic evaluation of the root of Berberis aristata Nat Prod Sci. 2001;7:102–6.
  20. Rokade M, Vichare V, Neve T, Parande B, Dhole S. A review on anticancer potential of Berberis aristata and berberine with focus on quantitative methods. J Prev Diagn Treat Strategies Med. 2022;1:67–75.
  21. Uniyal MR, Tewari LC. Anti-cancer drugs from U.P. Himalaya. Ancient Sci Life. 1991;11(1–2):50–5.
  22. Kokate CK. Phytochemical screening. In: Practical Pharmacognosy. New Delhi: Vallabha Prakshan; 1994. p. 107–11.
  23. Graham JG, Quinn ML, Fabricant DS, Farnsworth NR. Plants used against cancer – An extension of the work of Jonathan Hartwell. J Ethnopharmacol. 2000;73:347–77.
  24. Mayer BN, Forrigni NR, McLaughlin JC. A convenient general bioassay for active plant constituents. Planta Med. 1982;45:31–4.
  25. Kuo CL, Chou CC, Yung BY. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett. 1995;93:193–200.
  26. Letasiová S, Jantová S, Múcková M, Theiszová M. Antiproliferative activity of berberine in vitro and in vivo. Neoplasma. 2005;52(3):191–5.
Regular Issue Subscription Original Research
Volume 03
Issue 02
Received 16/05/2025
Accepted 28/06/2025
Published 23/08/2025
Publication Time 99 Days
54

Login


My IP

PlumX Metrics